3 days Ago By Defense World Staff
Arvinas, Inc. ( NASDAQ:ARVN – Get Free Report ) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 8,800,000 shares, a decline of 5.
6% from the October 15th total of 9,320,000 shares. Based on an average trading volume of 545,500 shares, the days-to-cover ratio is presently 16.1 days.
Institutional Investors Weigh In On Arvinas Several large investors have recently made changes to their positions in ARVN. M&T Bank Corp grew its holdings in Arvinas by 53.5% in the 3rd quarter.
M&T Bank Corp now owns 27,137 shares of the company’s stock worth $669,000 after buying an additional 9,462 shares in the last quarter. Barclays PLC boosted its position in Arvinas by 198.9% during the 3rd quarter.
Barclays PLC now owns 121,699 shares of the company’s stock worth $2,998,000 after acquiring an additional 80,984 shares during the period. Nomura Asset Management Co. Ltd.
grew its stake in shares of Arvinas by 36.3% in the third quarter. Nomura Asset Management Co.
Ltd. now owns 90,870 shares of the company’s stock worth $2,238,000 after purchasing an additional 24,223 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Arvinas during the third quarter valued at $453,000.
Finally, Zacks Investment Management raised its stake in shares of Arvinas by 9.8% during the third quarter. Zacks Investment Management now owns 89,827 shares of the company’s stock valued at $2,212,000 after purchasing an additional 8,029 shares in the last quarter.
Institutional investors and hedge funds own 95.19% of the company’s stock. Analyst Upgrades and Downgrades ARVN has been the subject of a number of analyst reports.
HC Wainwright reissued a “buy” rating and issued a $87.00 price target on shares of Arvinas in a report on Thursday, October 31st. Stephens initiated coverage on shares of Arvinas in a research report on Monday.
They set an “overweight” rating and a $55.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a report on Monday, September 9th.
Oppenheimer decreased their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 31st.
Finally, Wedbush reissued an “outperform” rating and issued a $57.00 target price on shares of Arvinas in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company.
Based on data from MarketBeat.com, Arvinas has an average rating of “Moderate Buy” and an average price target of $59.62.
Arvinas Price Performance NASDAQ:ARVN opened at $21.64 on Wednesday. Arvinas has a 12-month low of $20.
28 and a 12-month high of $53.08. The business has a 50 day simple moving average of $25.
66 and a 200 day simple moving average of $27.09. The firm has a market capitalization of $1.
49 billion, a P/E ratio of -4.63 and a beta of 1.96.
Arvinas ( NASDAQ:ARVN – Get Free Report ) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.
88) by $0.20. The firm had revenue of $102.
40 million for the quarter, compared to the consensus estimate of $60.56 million. The firm’s revenue was up 196.
0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.18) EPS.
Research analysts anticipate that Arvinas will post -3.32 EPS for the current fiscal year. Arvinas Company Profile ( Get Free Report ) Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Featured Articles Five stocks we like better than Arvinas Industrial Products Stocks Investing Super Micro Computer Soars 28%: Is It Really Out of the Woods? What are earnings reports? Traders Are Flocking Back to Oil: What’s Fueling the Optimism Find and Profitably Trade Stocks at 52-Week Lows 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter .
.
